Ioannidis J P, Rosenberg P S, Goedert J J, Ashton L J, Benfield T L, Buchbinder S P, Coutinho R A, Eugen-Olsen J, Gallart T, Katzenstein T L, Kostrikis L G, Kuipers H, Louie L G, Mallal S A, Margolick J B, Martinez O P, Meyer L, Michael N L, Operskalski E, Pantaleo G, Rizzardi G P, Schuitemaker H, Sheppard H W, Stewart G J, Theodorou I D, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zagury J F, O'Brien T R
Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110, Greece.
Ann Intern Med. 2001 Nov 6;135(9):782-95. doi: 10.7326/0003-4819-135-9-200111060-00008.
Studies relating certain chemokine and chemokine receptor gene alleles with the outcome of HIV-1 infection have yielded inconsistent results.
To examine postulated associations of genetic alleles with HIV-1 disease progression.
Meta-analysis of individual-patient data.
19 prospective cohort studies and case-control studies from the United States, Europe, and Australia.
Patients with HIV-1 infection who were of European or African descent.
Time to AIDS, death, and death after AIDS and HIV-1 RNA level at study entry or soon after seroconversion. Data were combined with fixed-effects and random-effects models.
Both the CCR5-Delta32 and CCR2-64I alleles were associated with a decreased risk for progression to AIDS (relative hazard among seroconverters, 0.74 and 0.76, respectively; P = 0.01 for both), a decreased risk for death (relative hazard among seroconverters, 0.64 and 0.74; P < 0.05 for both), and lower HIV-1 RNA levels after seroconversion (difference, -0.18 log(10) copies/mL and -0.14 log(10) copies/mL; P < 0.05 for both). Having the CCR5-Delta32 or CCR2-64I allele had no clear protective effect on the risk for death after development of AIDS. The results were consistent between seroconverters and seroprevalent patients. In contrast, SDF-1 3'A homozygotes showed no decreased risk for AIDS (relative hazard for seroconverters and seroprevalent patients, 0.99 and 1.03, respectively), death (relative hazard, 0.97 and 1.00), or death after development of AIDS (relative hazard, 0.81 and 0.97; P > 0.5 for all).
The CCR5-Delta32 and CCR2-64I alleles had a strong protective effect on progression of HIV-1 infection, but SDF-1 3'A homozygosity carried no such protection.
关于某些趋化因子和趋化因子受体基因等位基因与HIV-1感染结局的研究结果并不一致。
研究基因等位基因与HIV-1疾病进展之间的假定关联。
个体患者数据的荟萃分析。
来自美国、欧洲和澳大利亚的19项前瞻性队列研究和病例对照研究。
欧洲或非洲裔的HIV-1感染患者。
艾滋病发病时间、死亡时间、艾滋病发病后的死亡时间以及研究入组时或血清转化后不久的HIV-1 RNA水平。数据采用固定效应模型和随机效应模型进行合并。
CCR5-Δ32和CCR2-64I等位基因均与艾滋病进展风险降低相关(血清转化者中的相对风险分别为0.74和0.76;两者P值均为0.01),死亡风险降低(血清转化者中的相对风险分别为0.64和0.74;两者P值均<0.05),以及血清转化后较低的HIV-1 RNA水平(差异分别为-0.18 log(10)拷贝/毫升和-0.14 log(10)拷贝/毫升;两者P值均<0.05)。携带CCR5-Δ32或CCR-64I等位基因对艾滋病发病后的死亡风险没有明显的保护作用。血清转化者和血清阳性患者的结果一致。相比之下,SDF-1 3'A纯合子在艾滋病发病风险(血清转化者和血清阳性患者的相对风险分别为分别为0.99和1.03)、死亡风险(相对风险分别为0.97和1.00)或艾滋病发病后的死亡风险(相对风险分别为0.81和0.97;所有P值均>0.5)方面均未显示出风险降低。
CCR5-Δ32和CCR2-64I等位基因对HIV-1感染进展具有强大的保护作用,但SDF-1 3'A纯合性则没有这种保护作用。